 
NIH-FDA Clinical Trial Protocol Template – v1.07 Aug 2018   
A Phase 4 Study to Assess the Clinical Efficacy and 
Safety of Intense Pulse Light Treatm ent with 
Meibomian Gland Expression of the Upper Eyelids in 
Dry Eye  
 
Protocol Number: TCLUM -0012  
National Clinical Trial (NCT) Identified Number:  
Principal Investigator: Melissa Toyos, M  
 Sponsor: Toyos Clinic  
Funded by :unrestricted grant from Lumenis  
Version Number:  v.1 
27 Aug  2018  
 
 
NIH-FDA Clinical Trial Protocol Template – v1.07 Aug 2018   Table of Contents  
Funded by: unrestricted grant from Lumenis  ................................ ................................ ................................ ... ii 
Version Number:  v.1  ................................ ................................ ................................ ................................ ...............  ii 
27 Aug 2018  ................................ ................................ ................................ ................................ ................................  ii 
Table of Contents  ................................ ................................ ................................ ................................ ..........................  ii 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  1 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  1 
1.2 Schema  ................................ ................................ ................................ ................................ .................  2 
Example #1 Flow diagram (e.g., randomized controlled trial)  ................................ ................................ ......................  2 
Prior to  3 
Visit 1  3 
Visit 2  3 
Visit 3  3 
1.3 Schedule of Activities (SoA)  ................................ ................................ ................................ ...............  6 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  6 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 6 
2.2 Background ................................ ................................ ................................ ................................ ...........  6 
2.3 Risk/Benefit A ssessment  ................................ ................................ ................................ ....................  7 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ..... 7 
2.3.2  Known Potential Benefits  ................................ ................................ ................................  7 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................................  7 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ................  8 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ .............  8 
4.1 Overall Design  ................................ ................................ ................................ ................................ ...... 8 
4.2 Scientific Rationale for Study Design ................................ ................................ ................................  9 
4.3 Justification for Dose  ................................ ................................ ................................ ...........................  9 
4.4 End of Study Definition  ................................ ................................ ................................ .......................  9 
5 STUDY POPULATION  ................................ ................................ ................................ ................................ .. 9 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................ .. 9 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  10 
5.3 Screen Failures  ................................ ................................ ................................ ................................ .. 11 
5.4 Strategies for Recruitment and Retention  ................................ ................................ ......................  11 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  11 
6.1 Study Intervention(s) Administration  ................................ ................................ ...............................  11 
6.1.1  Study Intervention Description  ................................ ................................ .....................  11 
6.1.2  Dosing and Administration  ................................ ................................ ............................  11 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  12 
6.2.1  Acquisition and accountability  ................................ ................................ ......................  12 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ... Error! Bookmark not defined.  
6.2.3  Product Storage and Stability  ................................ ................................ .......................  12 
6.2.4  Preparation  ................................ ................................ ................................ ......................  12 
6.3 Measures t o Minimize Bias: Randomization and Blinding  ................................ ...........................  12 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  12 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  12 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ............  13 
7 STUDY IN TERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ................................ ....................  13 
 
NIH-FDA Clinical Trial Protocol Template – v1.07 Aug 2018   7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  13 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  13 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  14 
8 STUDY AS SESSMENTS AND PROCEDURES  ................................ ................................ .....................  14 
8.1 Efficacy Assessments  ................................ ................................ ................................ .......................  14 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  15 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  15 
8.3.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  15 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  16 
8.3.3  Classification of an Adverse Event  ................................ ................................ ..............  16 
OR 16 
8.3.4  Time Period and Frequency for Event Assessment and Follow -Up .......................  17 
8.3.5  Adverse Event Reporting  ................................ ................................ ..............................  18 
8.3.6  Serious Adverse Event Reporting  ................................ ................................ ...............  18 
8.3.7  Reporting Events to Participants  ................................ ................................ .................  18 
8.3.8  Events of Special Interest  ................................ ................................ .............................  19 
8.3.9  nReporting of Pregnancy  ................................ ................................ ..............................  19 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  19 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 19 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  19 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  20 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  20 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  20 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  20 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  20 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  20 
9.4.1  General Approach  ................................ ................................ ................................ ..........  21 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ .............................  21 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  21 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  21 
9.4.5  Base line Descriptive Statistics  ................................ ................................ .....................  21 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  21 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 21 
9.4.8  Tabulation of Individual participant Data  ................................ ................................ .... 21 
9.4.9  Exploratory Analyses  ................................ ................................ ................................ ..... 22 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............................  22 
10.1 Regulatory, Ethical, and Study Oversight Considerations  ................................ ...........................  22 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  22 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  22 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  23 
All research activities will be conducted in as private a setting as possible.  ................................ ...................  23 
10.1.4  Future Use of Stored Specimens and Data  ................................ ...............................  24 
10.1.5 Key Roles and Study Governance  ................................ ................................ ..............  24 
10.1.6  Safety Oversight  ................................ ................................ ................................ .............  24 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ..........  25 
10.1.8  Quality Assurance and Quality Control  ................................ ................................ .......  25 
10.1.9  Data Handling and Record Keeping  ................................ ................................ ............  25 
 
NIH-FDA Clinical Trial Protocol Template – v1.07 Aug 2018   10.1.10  Protocol Deviations  ................................ ................................ ................................ ........  26 
10.1.11  Publication and Data Sharing Policy  ................................ ................................ ...........  26 
10.1.12  Conflict of Interest Policy  ................................ ................................ ..............................  27 
10.2 Additional Considerations  ................................ ................................ ................................ .................  27 
10.3 Abbreviations  ................................ ................................ ................................ ................................ ...... 28 
10.4 Protocol Amendment History  ................................ ................................ ................................ ...........  29 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  31 
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  1 STATEMENT OF COMPLIA NCE  
 
 
(1) [The trial will be conducted in accordance with I nternational Conference on Harmonisation Good  
Clinical Practice ( ICH GCP)  and applicable United States (US) Code of Federal Regulations  (CFR) . 
The Principal Investigator will assure that n o deviation from, or changes to  the protocol will take 
place without prior agreement from the Investigational New Drug (IND) or Investigational Device 
Exemption (IDE) sponsor , funding agency  and documented approval from the Institutional 
Review Board ( IRB), except where necessary to eliminate an immediate hazard(s) to the trial 
participants. All personnel involved in t he conduct of this study have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 
form must be obtained before any participant is enrolled.  Any amendment to the protocol will 
require review and approval by the IRB before the changes are implemented to the study.  All 
changes to the consent form will be IRB approved; a determination will be made regarding 
whether  a new consent needs to be obtained from participants who provided consent, using a 
previously  approved consent form .] 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  A Phase 4 Study to Assess the Clinical Efficacy  and Safety of Intense Pulse 
Light with Meibomian Gland Expression of the Upper Eyelids in Dry Eye 
Disease  
Study Des cription : This study will  test the efficacy and safety of application of light and 
expression of meibomian  glands in upper eyelids in eyes of patients 
suffering with meibomian gland disease  unrelieved by traditional dry eye 
treatments.  
Objectives:  
 The primary objective of the study is to investigate the safety and efficacy 
of intense pulse light with Meibomi an gland expression of the upper eyelids 
in dry eye disease.  
  
  
Endpoint s: Primary Endpoi nt: Improvement of tear break up time over the length of 
the study  
 
Secondary endpoint: patient comfort over the length of the study using a 
validated dry eye comfort questionnaire, VAS, over the past 2 weeks. 0= 
no pain and 100 = maximal discomfo rt, Improvement of patient comfort 
over the past 24 hours using a validated dry eye comfort questionnaire, 
VAS, where 0=no pain and 100= maximal pain, and a VAS sca le of 
frequency of ocular discomfort over the past 24 hours where 0=no 
episodes and 100 = constant and continuous painful ocular episodes.  
Study Population:  19 study subjects 18 -85 will be enrolled with  male or female in the 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  2 Memphis , TN area who are gener ally healthy but have persistent signs and 
symptoms of dry eye diseases after treatment with traditional dry eye 
treatments including but not limited  to: IPL, cyclosporine , lifitegrast, 
loteprednol, artificial tears and warm compresses  
Phase:  4 
Description of 
Sites /FacilitiesE nrolling 
Participants : Single site study in Memphis , TN and surrounding areas.  
Description of 
Study Intervention : Upper eyelid intense pulse light is given tragus to tragus including nose for 
2 passes using standardized light settings and expression of Meibomian 
glands is done immediately following using cotton tip appli cators.  
Study Duration:  6 months  
Participa nt Duration:  8-12 weeks  
  
1.2 SCHEMA  
Flow diagram  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  3 Prior to  
Enrollment : 
 
 
 
 
 
 
 
Visit 1  
Time Point  
 
 
 
Visit 2  
Time Point  
 
 
Visit 3  
Time Point  
 
 
 
 
 
 
 
 
 
  Total N:  Obtain informed consent. Screen potential participants  by inclusion and 
exclusion  criteria; obtain history, document.  
Perform baseline assessments.written and informed consent, ocular and systemic 
medical history  
Visual analog  subject rated assessments, Slit lamp biomicroscopy, dilated fundus exam. 
Administer initial study intervention.  
Concomitant medications, adverse events, visual analog assessments, slit lamp 
biomicroscopy, study intervention  
Final Assessments  
<Concomitant medications, adverse 
events, subject rated assessments by 
visual analog scales, study intervention, 
slit lamp biomicroscopy, dilated fundus 
exam, dilated ophthalmoscopy, urine 
pregnancy test if needed, release of 
subject form the study > Arm 1  
N=19particii
pantsN 
participants  
Concomitant medications, adverse events,, slit lamp biomicroscopy, study intervention  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  4  
  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  5  
 
 
  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  6 1.3 SCHEDULE OF ACTIVITIES (SOA)  
u 
Procedures  
Screening  
Day -7 to -1 
Enrollment/Baseline  
Visit 1, Day 1  
Study Visit 2  
Day 14   +/-1 day  
Study Visit 3  
Day 28  +/- 1 day  
Final Study Visit 4  
Day 44  +/-1 day  
Informed consent  X     
Demographics  X     
Medical history  X     
Randomization  X     
      
Concomitant  med ication 
review  X X----------------------------------------------
-----------------------------------------------
X 
Bcva X X   X 
Slit lamp biomicroscopy  X x X x X 
Intense pulse light to upper 
lids  x X X X 
Expression of upper 
Meibomian glands  X X  X X 
Non-invasive tear break up 
time  X X  X X 
 X X x X X 
      
Dilated ophthalmoscopy  X    X 
  
 
 
 
\      
 
 
2  INTRODUCTION  
2.1 STUDY R ATIONALE  
Many people suffer from dry eye disease and are incompletely relieved of signs and symptoms with 
traditional treatments like artificial tears, warm compresses, prescription eye drops, and IPL. Those most 
severely affected may find relief using a systemic m edication that increases the body’s endogenous 
production of corticosteroid to reduce surface inflammation. This study will attempt to demonstrate 
improvement in both signs and symptoms of dry eye and the safety of use of this medicine in patients 
sufferin g with moderate to severe dry eye.  
 
2.2 BACKGROUND  
 
In 2002, Toyos and colleagues  observed that rosacea subjects treated with IPL showed improvement in 
symptoms of dry eye disease. They hypothesized that IPL application to the malar region and nose 
closes the  abnormal telangiectasias, decreasing the secretion of inflammatory substances and improving 
the function of Meibomian glands and the quality of their secretions.  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  7 Since this discovery, Toyos and colleagues have used IPL off -label to treat hundreds of rosacea subjects 
presenting with dry eye disease. A case report from 2002 demonstrated the potential of IPL technology 
for treatment of dry eye disease. Prior to the IP L sessions, the subjects reported unbearable drdy eye 
symptoms unresponsive to other conservative means of therapy (artificial tears, punctal plugs, 
cyclosporine, etc). After 4 monthly applications of IPL, there was a dramatic improvement in tear break 
up time and in Schirmer’s test. A more recent study showed improvements in TBUT and the OSDI 
questionnaire, shifting the level of disease downwards towards less symptoms.  
 
The M22 is modular. The M22 comprises the IPL module (treatment head and handpi ece – Universal IPL 
Sapphire Cool Light Guide 6 mm KT -1007656) hereby referred to as the M22 with Optimal Pulse 
Technology, or M22 -OPT.  
 
The IPL treatment head emits light in the range of 515 -1200 nm. The light is emitted perpendicular to 
the handpiece axis. The tip (lightguide) is made of sapphire and provides coverage of 6 mm. The 
lightguide is cooled by a thermos -electric cooler (also referred to as a chiller).  
2.3 RISK/BENEFIT ASSESSM ENT  
 
2.3.1  KNOWN POTENTIAL RISKS  
 
Known risks of IPL  on skin  and Meibomian expression  include  
Skin redness  
Eye redness  
Skin blistering  
Skin pigmentation  
Skin swelling  
Lid swelling  
Lid tenderness  
Increased mucus production  
Skin scarring  
 
 
2.3.2  KNOWN POTENTIAL BENE FITS  
 
 
IPL is known to improve the signs and symptoms of dry eye disease including OSDI scores, tear break up 
time and eye comfort when four or more treatments are utilized over time. IPL also appears to improve 
the quality of Meibomian secre tion and the function  of Meibomian glands .  
 
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
Moderate to severe dry eye can cause significant discomfort and interfere with even daily normal 
function. Patients can experience depression , reduced function at work , social anxiety if others 
incorrectly interpret red eyes as staying out too late, use of illegal drugs or episodes of crying. Patients 
who have exhausted all currently available therapies and still experience bothersome signs and 
symptoms especially if sy mptoms interfere with jobs and normal daily function may feel that the 
increased risk of topical light therapy to affected periocular skin coupled with Meibomian gland 
expression may be worth the benefits of reduced ocular surface inflammation.  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  8 3 OBJECTIVES  AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Primary    
The primary objective is the safety 
and efficacy of intense pulse light 
treatment with meibomian gland 
expression in upper lids with 
documented moderate to severe 
dry eye disease who have failed 
traditional therapies.  
 The primary endpoint  is the  
improvement in non-invasive tear 
break up time over the course of the  
study.  Endpoint  has been 
validated in prior  dry 
eye approvals . 
Secondary    
The s econdary objective s are 
improvement in ocular pain and 
reduction of episodes of eye pain 
due to dry eye.  The second ary endpoint (s)are 
improvement in eye pain due to dry 
eye over the course of the trial with a 
validated dry eye comfort 
questionnaire, measuring VAS pain 
scale over the past 2 weeks  and 24 
hours  on a scale of 0 -100 with 0 being 
no pain and 100 being maximal 
continuous pain. Also VAS scale 
measurement at each study visit 
measuring the frequency of ocular 
pain episodes  over the previous 2 
weeks on a scale of 0-100 with 0 
being no episodes of eye pain due to 
dry eye and 100 being continuous 
maximal eye pain due to dry eye.  Endpoint s have been 
validated in recent dry 
eye approvals 
(lifitegrast).  
   
. . 
  
 
 
 
 
 
 
 
 
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
• The hypothesis is that use of upper eyelid IPL coupled with Meibomian gland expression has the 
ability to reduce ocular surface inflammation in moderate to severe dry eye and improve the 
signs and symptoms over the course of the trial.  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  9  
• Single site pilot study Pilot study  
• Intense pulse light with Meibomian gland expression  will be applied tragus to tragus including 
the nose four times every two weeks  to control signs and symptoms at the discretion of the 
primary investigator.  
 
• One study arm of activ e intervention for up to 12 weeks  
• Single  site 
• Study interv ention is use of intense pulse light with Meibomian gland expression of both upper 
eyelids  
• No interim analysis is planned  
There are no planned stratifications.  
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
This is a small single site study with no control designed to show safety and efficacy in moderate to 
severe dry eye disease which may be used in the future as a basis for a larger, multi -site, randomized 
placebo controlled study.  Potential pitfalls include the small number of participants, the variable nature 
of the disease and the often inverse relationship of signs to symptoms in dry eye disease.  
 
4.3 JUSTIFICATION FOR DO SE 
Recommended IPL settings correlate to the Fitzpatrick skin  type and are the Toyos settings utilized in 
previous trials and in current practice. These values are recommended and can be modified at the 
discretion of the investigator.  
 
Skin Type  Fluence  Filter nm  Pulse 
structure  Pulse 
duration 
msec  Delay 
msec  Chiller  
I 10 590 triple  6 50 On 
II 10 590 triple  6 50 On 
III 10 590 triple  6 50 On 
IV 10 590 triple  6 50 On 
 
4.4 END OF STUDY DEFINITION  
A participant is considered to have completed the study if he or she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the S chedule of Activities (SoA), 
Section 1.3 . 
 
 
5 STUDY POPULATION  
 
 
5.1 INCLUSION CRITERIA  
 
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  10 1. Provision of signed and dated informed consent form  and HIPPA authorization.  
2. Stated willingness to comply with all study procedures and availab ility for the duration of the 
study  
3. Male or female, age d 18 -85. 
4. Diagnosed with moderate to severe dry eye in one or both eyes.  
5. History of persistent symptoms despite use of artificial tears and one or more of the following  
ophthalmic drops :loteprednol, cyclosporine or lifitegrast.  
6. Tear break up time of 7 seconds or less  
7. Have normal lid anatomy.  
8. Fitzpatrick skin type I -IV. 
9. Subject is able and willing to comply with the treatment, follow up schedule and requirements.  
10. For female s of reproductive potential :use of highly effe ctive  contraception for at least 1 month 
prior to screening and agreement to use such a method during study participation and for an 
additional  4 weeks after the end of the study.  
11. For male s of reproductive potential :use of  condoms  or other methods to ensure effective 
contraception with partner  
12. Are postmenopausal (no menstrual cycle for at least one year prior to Visit 1) or have undergone 
bilateral tubal ligation, hysterectomy, hysterectomy with uni - or bilateral oophorectomy, or 
bilateral oophorectomy.  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
1. Have a known hypersensitivity or contraindication to the i nvestigational product or 
components.  
2. Pregnancy or lactation  
3. Subjects can be on the following medications if they have been on a stable dose for 12 weeks: 
topical cyclosporin e, topical liftigrast and/or topical loteprednoletabonate. Tetracycline 
compounds, omega 3s, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic 
immunosuppressive agents i ncluding oral corticosteroids, non -steroidals, antihistamines, or 
mast cell stabilizers, punctal plugs, contact lens wear and glaucoma medications.  
4. Subjects must be unwilling to abstain from eyelash growth medications for the duration of the 
trial.  
5. Subjec ts must not have had penetrating intraocular surgery, refractive surgery or corneal 
transplantation, eyelid surgery within 12 weeks prior to Visit 1.  
6. Febrile illness within one week.  
7. Treatment with another investigational drug or other intervention within  one month.  
8. Subjects with a history of herpetic keratitis.  
9. Have serious or severe disease or uncontrolled medical condition that in the judgement of the 
investigator could confound study assessments or limit compliance.  
10. Neuro -paralysis or pre -cancerous l esions in the area to be treated.  
11. Prior history of cold sores or rashes in the area to be treated.  
12. Use of photosensitizing medication within the past 90 days including isotretinoin, tetracycline, 
doxycycline and St. John’s Wort.  
13. Radiation to the head or ne ck within past 12 months.  
14. Planned radiation therapy or chemotherapy.  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  11 15. Anticipated relocation or extensive travel outside of the local study area preventing compliance 
with study procedures.  
16. Legally blind in either eye.  
17. Facial IPL treatment within 12 months of treatment.  
18. Expression of Meibomian glands within 6 months prior to treatment.  
 
 
 
5.3 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure participants ,to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, screen 
failure details, eligibility criteria, and any serious adverse event (SAE).  
 
 
5.4 STRATEGIES FOR RECRU ITMENT AND RETENTION  
 
Anticipate 20 screenings for 15  enrolled su bjects.  
 One site in the US.  
 Source of participant s will be outpatient clinics and general public  
 Potential participant s will be identified and approached  by chart review, during regular dry eye 
clinic visits and self -identified by general dry eye study signs within our clinics  
 
6 STUDY INTERVENTION  
The study intervention is the use of intense pulse light with M22 machine with 6 mm light guide applied 
across bilateral upper lids tragus to tragus including the nose followed by expression of the meibomian 
glands with fingers and/or cotton q -tips. Patients will be given one drop of bromfenac and one drop of 
brimonidine following the treatment and given one bottle of bromfenac to be used once daily for four 
days following the procedure.  
 
6.1 STUDY INTERVENTION (S)ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION DESCRIPTION  
There is no control, only study intervention with intense pulse light and Meibomian gland expression of 
bilateral upper lids. This treatment  will be studied in this investigation specifically for moderate to severe 
dry eye disease.  
 
 
6.1.2  ADMINISTRATION  OF TRE ATMENT  
Each eligible participant will undergo IPL therapy using the M22 OPT machine. Eye shields will be placed 
on the lower lids, leaving upper lids exposed for the treatment. Ultrasound coupling gel applied 1 -2 mm 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  12 thick across the area of treatment will be applied tragus to tragus across the area to be treated. Two 
passes of light at a power setting of 10 mJ were used across the upper eyelids.  
 
 
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  ACQUISITION  
The investigative site will provide M22, specified lightguide, coupling agent , bromfenac, brimonidine  and 
Honeywell adhesive eye protection as well as eye protection glasses for operators.  
.  
 
6.2.2  TRAINING  
Investigators and study staff will be fully trained on the protocol and the appropriate study techniques  by Dr. 
Rolando Toyos or doctors trained by directly by Dr. Rolando Toyos.  
 
6.2.3  PRODUCT STORAGE  
The M22 and corresponding handpiece will be stored in the clinic at room temperature between 65 -80 degrees 
Fahrenheit.  
 
 
6.2.4  PREPARATION  
Before treatment, the subjects  face will be cleaned with a mild cleansing agent like soap, facial wipes or dilute 
medical grade alcohol. Clinicians will be trained to identify Fitzpatrick skin types, apply a thin film of coupling gel 
and use appropriate eye protection for subjects as w ell as staff.  The treatment area will include the upper eyelids 
from tragus to tragus including the nose.  
 
6.3 MEASURES TO MINIMIZE  BIAS : RANDOMIZATION  AND BLINDING  
 All subjects will receive active drug with no control.  
 
 
6.4 STUDY INTERVENTION COMPLIANCE  
Adherence to the protocol  will be assessed by documenting study visits.  
 
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. Medications to be reported in the Case Report Form ( CRF) are 
concomitant prescription medications, over -the-counter medications and supplements . 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  13  
 
6.5.1  RESCUE MEDICINE  
The study sitewill notsupply rescue medication . 
 
The use of rescue medications i s allowable at any time during the study  and t he date and time of rescue 
medication administration as well as the name and dosage regimen of the rescue medication must be 
recorded.  
 
 
 
7 STUDY INTERVENTION DISCONTINUATION AND 
PARTICIPANT DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTIO N 
 
Discontinuation during study  does not mean discontinuation from the study, and remaining study 
procedures should be completed as indicated by the study protocol. If a clinically sig nificant finding is 
identified (including, but not limited to changes from baseline) after enrollment, the investigator or 
quali fied designee will determine if any change in participant management is needed. Any new clinically 
relevant finding willbe reported as an adverse event (AE) . 
 
The data to be collected at the time of study intervention discontinuation will include the following:  
 Subject rated assessment of eye dryness, past 2 weeks and 24 hours, subject assessment of 
frequency of eye pain related to dry eye,  use of concomitant medic ations since last visit, 
occurrence of AEs sinc e last visit, BCVA, slit lamp biomicroscopy,  dilated fundus exam and 
pregnancy test for women of childbearing potential.  
 
7.2 PARTICIPANT DISCONTINUATION /WITHDRAWALFROM THE STUDY  
 
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue or withdraw a participa nt from  the study for the following reasons : 
 
 Pregnancy  
 Significant study intervention non-compliance  
 If any clinical adverse event (AE), labor atory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant  
 Disease progression which requires discontinuation of the study intervention  
 If the partic ipant  meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
 Participant unable to receive study intervention for 20 days . 
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case 
Report Form ( CRF).Subjects who sign the informed consent form and are randomized but do not receive 
the study intervention may be replaced.  Subjects who sign the informed consent form, and are 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  14 randomized and receive the study intervention , and subsequently withdraw, or are withdrawn or 
discontinued from the study, will be replaced.  
 
7.3 LOST TO FOLLOW -UP 
A participant will be considered lost to follow -up if he or she fails to return for 2 scheduled v isits and is 
unable to be contacted by the study site  staff .  
 
The following actions must be taken if a participant fails to return to the clinic for a required study visit:  
 The site willattempt to contact the participant and reschedule the missed visit within 72 hours 
and counsel the participant on the importance of maintaining the assigned visit schedule and 
ascertain if the participant wishes to and/or should continue in the study.  
 Before a participant is deemed lost to follow -up, the investigator or d esignee willmake every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, 
a certified letter to the participant’s last known mailing address or local equivalent methods). 
These contact attempts should be doc umented in the participant’s medical record or study file.  
 Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary rea son o f lost to follow -up. 
 
 
8 STUDY ASSESSMENTS AN D PROCEDURES  
. 
 
8.1 EFFICACY ASSESSMENTS  
List and describe all study procedures and evaluations to be done as part of the study  to support the 
determination of efficacy , as per the primary and secondary objectives outlined in this protocol . Discuss 
the sequence of events that should occur during the screening  process  and any decision points regarding 
participant eligibility.  Include  the time frame prior to enrollment within which screening procedures/  
evaluations must be performed (e.g., within 28 days prior to enrollment).  
 
In addition, indicate where appropriate, that procedures/evaluations will be performed by qualified 
personnel.  
 
 Each subject will undergo 4 treatment sessions at 2 weeks intervals.  
 Once enrolled, initial study visit will occur within one week and can occ ur on the same day. Study 
assessments on each study day will occur in this order:  
 Subject rated assessment of ocular discomfort by visual analog scale. Subjects will be asked to 
subjectively rate their eye dryness for the past 2 weeks and the past 24 hours  at Visit 1,2, 3 
and 4 . Subjects will be instructed to rate eye dryness using the scale below. The total length of 
the line from “no dryness” to “maximal dryness” is 100 mm. The length of the line between the 
“no dryness” starting point and the first point  at which the subject mark crosses the line will 
be measured in mm. This assessment is a general assessment of both eyes.  
Past 2 week and Instanta neous Evaluation of Eye Dryness  
 
Please place a single line across the line below to indicate the severity of your eye dryness at 
the present time:  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  15  
No dryness_________________________________________Maximal dryness  
 Subject rated assessment of frequency of ocular discomfort by visual analog scale. Subjects 
will be asked to subjectively rate their eye dryness for t he past 2 weeks at Visit 1,2, 3 and 4. 
Subjects will be instructed to rate the frequency of eye pain episodes using the scale below. 
The total length of the line from “no episodes” to “constant maximal episodes” is 100 mm. The 
length of the line between th e “no dryness” starting point and the first point at which the 
subject mark crosses the line will be measured in mm. This assessment is a general assessment 
of both eyes.  
Past 2 week and Instantaneous Evaluation of Eye Dryness  
 
Please place a single line a cross the line below to indicate the severity of your eye dryness at 
the present time:  
 
No eye pain episodes_________________________________________Maximal and 
continual eye pain episodes  
 
 Significant non -ocular and significant ocular medical history  
 Concomitant medication usage and significant medications taken 6 months prior to screening  
 Inclusion/Exclusion criteria  
 Urine pregnancy test if required  
 BCVA Subjects will be placed at the predetermined mark for ETD RS testing  
 Slit lamp biomicroscopy  – 8 mm x 2 mm slit lamp beam wil l be used right to left and left to 
right to examine thoroughly the structures of the anterior segment: lids, lashes, conjunctiva, 
corea, iris, anterior chamber, and lens.  
 Dilated ophthalmoscopy will occur at the first and last study visit and include assessment of 
the optic nerve head for pallor and cupping.  
 Non -invasive tear break up timewill be assessed su bjectively by the investigator using a stop 
watch and the average of 3 measurements will recorded at each of the 4 study visits.  
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 Slit lamp biomicroscopy – 8 mm x 2 mm slit lamp beam wil l be used right to left and left to 
right to examine thoroughly the structures of the anterior segment: lids, lashes, conjunctiva, 
cornea, iris, anterior ch amber, and lens.Results will be recorded as normal or abnormal. 
Abnormal findings will be followed by explanation of pathology.  
 Dilated ophthalmoscopy will occur at the first and last study visit and include assessment of 
the optic nerve head for pallor an d cupping.  
Adverse events will be collected at each time point  
 
h 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERS E EVENTS  (AE)  
Adverse event means any untoward medical occurren ce associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.3  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  16  
8.3.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
An adverse event ( AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it resul ts in any of the following outcomes: death, a life -threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life func tions, or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the participant  and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or con vulsions that do 
not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
 
 
8.3.3  CLASSIFICATION OF AN  ADVERSE E VENT  
 
8.3.3.1  SEVERITY OF EVENT  
For adverse events ( AEs) not included in the protocol defined grading system, the following guidelines 
will be used to describe severi ty. 
 
• Mild – Events require minimal or no treatment and do not interfere with the participant ’s daily 
activities.  
• Moderate –Events result in a low le vel of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant ’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe even ts are usually potentially life -threatening or 
incapacitating.   Of note, the term  “severe” does not necessarily equate to “serious” . 
 
 
8.3.3.2  RELATIONSHIP TO STUD Y INTERVENTION  
All adverse events ( AEs) must have their relationship to study intervention assessed  by the clinician who 
examines and evaluates the participantbased on temporal relationship and his/her clinical judgment. 
The degree of certainty about causality will be graded using the categories below. In a clinical trial, the 
study product must always be suspect.  
 
• Related  – The AE is known to occur with the study intervention , there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means  that there is evidence to suggest a causal 
relationship between the study intervention and the AE. 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship betw een the study 
intervention and event onset , or an alternate etiology has been established.  
 
OR 
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  17 • Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, inclu ding an abnormal laboratory test 
result, occurs in a plausible time relationship to study intervention administration and cannot be 
explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the 
study intervention (dechallenge ) should be clinically plausible. The event must be 
pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge 
procedure if necessary.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within 
a reasonable time after  administration of the study intervention , is unlikely to be attributed to 
concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on 
withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
• Potentially  Related – There is some ev idence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other 
factors may have contributed to the event (e.g., the participant ’s clinical condition, other 
concomitan t events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or 
“definitely related”, as appropriate.  
• Unlikely to be related – A clinical even t, including an abnormal laboratory test result, whose 
temporal relationship to study intervention administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administration of the 
study intervention ) and in which other drugs or chemicals or underlying disease provides 
plausible explanations (e.g., the participant ’s clinical condition, other concomitant treatments).  
• Not Related – The AE is completely independent of study intervention administration, and/or  
evidence exists that the event is definitely related to another etiology. There must be an 
alternative, definitive etiology documented by the clinician.  
 
 
8.3.3.3  EXPECTEDNESS  
: 
 
The primary investigator will be responsible for determining whether an adverse eve nt (AE) is expected 
or unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is 
not consistent with the risk information previously described for the study intervention . 
 
8.3.4  TIME PERIOD AND FREQ UENCY FOR EVENT ASSESSMENT AND FOLLO W-UP 
Describe how AEs and SAEs will be identified  and followed until resolved or considered stable .  Specify  
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention of 
study personnel during st udy visits and interviews of a study participant  presenting for medical care, or 
upon review by a study monitor.  
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate  case report form( CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the 
training and authority to make a diagnosis), and time of resolution/stabilization of  the event. All AEs 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  18 occurring while on study must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant  is screened will be considere d as 
baseline and not reported as an AE. However, if the study participant’s condition  deteriorates at any 
time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity  to be performed. A Es characterized as intermittent require documentation of 
onset and duration of each episode.  
 
The study coordinator will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study 
participation.  At each study visit, the study coordinator  will inquire about the occurrence of AE/SAEs 
since the last visit.  Events will be followed for ou tcome information until resolution or stabilization.  
 
 
8.3.5  ADVERSE EVENT REPORT ING  
 
8.3.6  SERIOUS ADVERSE EVEN T REPORTING  
 
 
The study clinician will immediately report to the sponsor any serious adverse event, whether or not 
considered study intervention related, including those listed in the protocol or investigator brochure and 
must include an assessment of whether there is a reasonable possibility that the study 
intervention caused the event. Study endpoints that are serious adverse events (e.g., all -cause mortality) 
must be reported in accordance with the protocol unless there is evidence suggesting a causal 
relationship between the study intervention and the event (e.g., death from anaphylaxis). In that case, 
the investigator must immediately report the event to the sponsor . 
 
All serious adverse events ( SAEs ) will be followed until satisfactory resolution or until the site 
investigator deems the event to be chronic or the participant is stable. Other supporting documentation 
of the event may be requested by the Data Coordinating Center ( DCC)/study sponsor and should be 
provided as soon as possible.  
 
The study sponsor will be responsible for notifying the Food and Drug Administration ( FDA) of any 
unexpected fatal or life -threatening suspected adverse reacti on as soon as possible , but in no case later 
than 7 calendar days after the sponsor's initial receipt of the information.   In addition, the sponsor must 
notify FDA and all participating investigators in an Investigational New Drug ( IND) safety report of 
potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later 
than 15 calendar days after the sponsor determines that the information qualifies for reporting .] 
 
 
8.3.7  REPORTING E VENT S TO PARTICIPANTS  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  19 Participants will be informed about AEs  and SAEs, and study -related  results on an individual or aggregate 
level.  Incidental findings associated with study  procedures  will be monitored by the primary investigator 
and reported appropriately as required.  
 
 
8.3.8  EVENTS OF SPECI AL INTEREST  
 
8.3.9  NREPORTING OF PREGNAN CY 
Should a participant become pregnant during the study, the primary investigator will create a plan to 
stop or taper the study drug as quickly as possible. The primary investigator will communicate with the 
physician managing the pregnancy and the subject a nd pregnancy will be followed to term.  
 
 
8.4 UNANTICIPATED PROBLE MS 
. 
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participant s or others to include, in general, any incident, experience, or outcome that meets all of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents , such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant  population being studied;  
• Related or possibly related to participation in the research (“possibly relate d” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places participant s or others at a greater risk of harm (including 
physica l, psychological, economic, or social harm) than was previously known or recognized.  
 
 
8.4.2  UNANTICIPATED PROBLE M REPORTING  
 
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB) and t o the Data Coordinating  Center ( DCC)/lead principal investigator ( PI). The UP report will 
include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP. 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  20  
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
 
• UPs that are serious adverse events ( SAEs) will be reported to the IRB and to the DCC/study 
sponsor within 24 hours of the investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the DCC/study sponsor within one week of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appropriate in stitutional officials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and the Office for 
Human Research Protections ( OHRP ) within 7 business days  of the IRB’s receipt of the report of 
the problem fr om the investigator.]  
 
 
8.4.3  REPORTING UNANTICIPA TED PROBLEMS  TO PARTICIPANTS  
Unanticipated problems affecting the study or study participants will be reported to subjects by the primary 
investigator as soon as they are known.  
 
9 STATISTICAL CONSIDER ATIONS  
 
9.1 STATISTICAL HYPOTHES ES 
State the formal and testable null and alternative hypotheses for primary and key secondary endpoints, 
specifying the type of comparison (e.g., superiority, equivalence or non -inferiority, dose response) and 
time period for which each endpoint will be analyzed.  
 
 Primary Efficacy Endpoint : the study will attempt to demonstrate the improvement in mean 
average from baseline to final visit of measure of pain in past 2 weeks on visual analog scale 
(VAS) scale.  
 Secondary Efficacy Endpoint( s):  the study will attempt to demonstrate the improvement in 
mean average f rom baseline to final visit of visual analog scale of pain over the previous 24 
hours an, the frequency of ocular discomfort over the past 2 weeks and the n on-invasive tear 
break u p time.  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
This is a small pilot study of 15  participants completing the study assessments. There is no placebo and it 
is not powered to show statistical significance.  
 
9.3 POPULATIONS FOR ANALYSES  
 
 Intention -to-Treat (ITT) Analysis Dataset (i.e., all randomized participant s) 
 Safety Analysis Dataset: defines the subset of participant s for whom safety analyses will be 
conducted (e.g., participant s who took at least one dose of study intervention ) 
 
9.4 STAT ISTICAL ANALYSES  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  21 Paired t -tests will be conducted for each VAS scale and TBUT with standard deviations, error means, 95% 
confidence intervals and level of significance.  
 
9.4.1  GENERAL APPROACH  
As a guide, the following should be addresse d, as appropriate:  
 
 Categorical and continuous data will be presente d as percentages, means with standard 
deviations, median, and range).  
 
9.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
 
The improvement of non-invasive tear break up time from the beginning of the study to the e nd.  
Descriptive st atistics and paired t -tests will be applied.  
 MIssing data will be  handled by imputation .Outliers will be evaluated by the primary 
investigator. Subjects who are nonadherent will be referred for re -training and those lost to 
follow up wil l be contacted by the study coordinator at least 3 times by phone and ultimately 
with certified letter if telephone contacts are unsuccessful.  
 
9.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
For each secondary endpoint:  
 
 The improvement of visual analog scale of pain over the past 2 weeks, the past 24 hours and the 
frequency of eye pain from dry eye over the past 2 weeks. Descriptive statistics  and paired t -
tests will be used where applicable.  
 
9.4.4  SAFETY ANALYSES  
 
Safety endpoints will be analyzed as summary statistics during treatment, coded as per Medical 
Dictionary for Regulatory Activities and counted once only for a given participant. Start/stop dates, 
severity as determined by the investigator, relationship, e xpectedness, outcome and duration will be 
reported. Adverse events leading to premature discontinuation from the study and serious treatment -
emergent AEs will be presented separately in a listing.  
 
9.4.5  BASELINE DESCRIPTIVE  STATISTICS  
Include content in this section if applicable, otherwise note as not -applicable . 
 
Because all subjects will receive active intervention, Intervention groups will not be compared . 
 
9.4.6  PLANNED INTERIM ANAL YSES  
No interim analysis is planned.  
 
9.4.7  SUB -GROUP ANALYSES  
No sub -group anal yses are planned.  
 
9.4.8  TABULATION OF INDIVI DUAL PARTICIPANT DATA  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  22 Individual participant  data will not be listed by measure and time point.  
1 
 
9.4.9  EXPLORATORY ANALYSES  
No e xploratory analyses are planned.  
 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  
. 
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PRO CESS  
 
10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO  
PARTICIPANTS  
  
 
Consent forms describing in detail the study intervention , study procedures, and risks are given to the 
participant  and written documentation of informed consent is required prior to starting 
intervention/administering study intervention .  The following consent materials are submitted with this 
protoc ol.: inform ed consent document.  
 
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be Institutional 
Review Board ( IRB)-approved and the participant  will be asked to read and review the document. The 
study coordinator and primary i nvestigator will explain the research study to the participant  and answer 
any questions that may arise. A verbal explanation will be provided in terms suited to the  participant’s 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 
research participants.  Participants will have the opportunity to carefully review the written consent 
form and ask questions prior to signing.  The participant s should have the opportunity to discuss the 
study with their family or surrogates or think about it prior to agreeing to participate. The participant  
will sign the informed consen t document prior to any procedures being done specifically for the study.  
Participant s must be informed that participation is voluntary and that they may withdraw from the 
study at any time, without prejudice.  A copy of the informed consent document will b e given to the 
participant s for their records  if requested . The informed consent process will be conducted and  
documented in the source document (including the date), and the form signed, before the participan t 
undergoes any study -specific procedures. The r ights and welfare of the participant s will be protected by 
emphasizing to them that the quality of their medical care will not be adversely affected if they decline 
to participate in this study.  
  
10.1.2  STUDY DISCONTINUATIO N AND CLOSURE  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  23  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to study p articipants, investigator, funding agency, the 
Investigational New Drug ( IND) or Investigational Device Exemption ( IDE) sponsor and regulatory 
authorities.  If the study is prematurely terminated or suspended, the  Principal Investigator ( PI) will 
promptly inform study participants, the Instituti onal Review Board ( IRB), and sponsor and will provide 
the reason(s) for the termination or suspension.  Study participants will be contacted, as applicable, and 
be informed of changes to study visit schedule.  
 
Circum stances that may warrant termination or suspension include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to participants  
 Demonstration of efficacy that would warrant stopping    
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 Determination that  the primary endpoint has been met  
 Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed , 
and satisfy the sponsor, IRB and/or Food and Drug Administration ( FDA).] 
 
 
 
10.1.3  CONFIDENTIALITY  AND PRIVACY  
 
 Initials  will be attached to data /samples  
 
 Personally identifiable information will be released to third parties such as insurance carriers and 
primary  physicians if warranted.  
 Study coordinator, primary and sub -investig ators will have  access to records, data, and samples.  
Monitors or auditors outside of study investigators will need access  as well.  
 
 
Participant  confidentiality  and privacy is strictly held in trust by the participating investigators, their 
staff, and the sponsor(s) and their intervention s. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relatin g to participa nts. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior wri tten approval of the sponsor.  
 
All research activities will be conducted in as private a setting as possible.  
 
The study monitor, other authorized representatives of the sponsor, representative s of the Institutional 
Review Board ( IRB), regulatory agencies  or pharmaceutical company supplying study product may 
inspect all documents and records required to be maintained by the investigator, including but not 
limited to, medical records (office, clinic, or hospital) and pharmacy records for the participant s in this 
study. The clinical study site will permit access to such records.  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  24  
The study participant’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the reviewing  IRB, Institutional policies, or sponsor requirements . 
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at  Toyos Clinic . This will not include the participant’s contact or identifying 
information. Rather, individual participants and their research data will be identified by a unique study 
identification number. The study data entry and study ma nagement systems used by  the clinic site and 
research staff will be secured and password protected. At the end of the study, all study databases will 
be de -identified and archived at Toyos Clinic.  
 
 
10.1.4  FUTURE USE OF STORED  SPECIMENS  AND DATA  
 
Data collected f or this study will be analyzed and stored at Toyos Clinic  onsite at 2204 Crestmoor 
Nashville, TN or in appropriate storage facility where Toyos Clinic records are kept . After the study is 
completed, the de -identified, archived data will be transmitted to a nd stored at Toyos Clinic.  for use by 
other researchers including those outside of the study.  
 
 
When the study is  completed , access to study data will be provided through  Toyos Clinic. ] 
 
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
Provide the name and contact information of the Principal Investigator and the Medical Monitor.  
Principal Investigator  
Melissa Toyos, MD partner  
Toyos Clinic  
2204 Crestmoor Nashville, TN  
615.327.44  
mtoyos@toyosclinic.com  
 
 
 
 
 
10.1.6  SAFETY OVERSIGHT  
 
Safety oversight will be under the direction of a n IRB and a Data and Safety Monitoring Board ( DSMB ) 
composed of individuals with the appropriate expertise, including studies and 
Actharspecifically. .Members of the DSMB should be independent from th e study conduct and free of 
conflict of interest, or measures should be in place to minimize perceived conflict of interest.  The DSMB 
will meet at least semiannually to assess safety and efficacy data on each arm of the study. The DMSB 
will operate under the rules of an approved charter that will be written and reviewed at the 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  25 organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will 
be clearly defined. The DSMB will provide its input to Toyos Clinic.  
 
 
10.1.7  CLINICAL MONITORING  
 
 
 
Clinical site monitoring is conducted to ensure that the rights and well -being of trial participants  are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with International 
Conference on Harmonisation Good Clinical Practice ( ICH GCP), and with applicable regulatory 
requirement(s).  
 
• The primary investigator will conduct the monitoring  on-site, once, fo r random review of 
certain data , safety. Independent auditswill not be conductedto ensure monitoring practices 
are performed consistently .] 
 
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
 
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen  collection, documentation and completion.  An individualized quality management plan will be 
developed to descr ibe a site’s quality management.  
 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the  site(s)  for clarification/resolution.  
 
Following written Standard Operating Procedures ( SOPs ), the monitors will verify that the clinical trial is 
conducted and data are generated  and biological specimens are collected , documented (recorded), and 
reported  in compliance with the protocol, International Conference on Harmonisation Good Clinical 
Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices ( GLP), Good 
Manufacturing Practices ( GMP )).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and 
regulatory author ities.  
 
 
 
10.1.9  DATA  HANDLING AND RECORD  KEEPING  
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIB ILITIES  
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  26 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
investigator . The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness  of the data reported . 
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.   
 
Hardc opies of the study visit worksheets  will be provided for use as source document  worksheets for 
recording data for each participant  enrolled in the study.   
 
Clinical data (including adverse events ( AEs), concomitant medications, and expected adverse reactions 
data) and clinical lab oratory data will be entered onto the CRF provided by Toyos clini c. 
 
10.1.9.2  STUDY RECORDS RETENT ION  
 
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 
application in an  International Conference on Harminosation ( ICH) region and until there are no pending 
or contemplated marketi ng applications in an ICH region or  until at least 2 years have elapsed since the 
formal discontinuation of clinical development of the study intervention . These documents should be 
retained for a longer period, however, if required by local regulations. No records will be destroyed 
without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform 
the investigator when these documents no longer need to be retained.  
 
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) requirements. The 
noncompliance may be either on the part of the participant , the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 
These practices are consiste nt with ICH GCP:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site investigator to use continuo us vigilance to identify and report 
deviations within  14 working days of identification of the protocol deviation, or within 14 working days 
of the scheduled protocol -required activity.  All deviations must be addressed in study source 
documents, reported to sponsor . .  Protocol deviations must be sent to the reviewing Institutional 
Review Board (IRB)  per their policies . The site investigator  is responsible for knowing and adhering to 
the reviewing IRB requirements.  
 
10.1.11  PUBLICATION AND DATA  SHARING POLICY  
This study is not funded by the NIH.  
 
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  27 10.1.12  CONFLICT OF  INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence , such as  by the pharmaceutical 
industry , is critical .  Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial  will be disclosed and managed . Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to th eir participation in the design and conduct of this t rial.  The study 
leadership in conjunction with the NIH I nstitute has established policies and procedures for all study 
group members to disclose all conflicts of interest and will establish a mechanism f or the management 
of all reported dualities of interest.]  
 
 
10.2 ADDITIONAL CONSIDERA TIONS  
Not applicable.  
  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  28 10.3 ABBREVIATIONS  
The list below  includes abbreviations utilized in this template.  However, this list should be customized for 
each protocol (i.e., abbreviations not used should be removed and new abbreviations used should be 
added to this list).  
 
AE Adverse Event  
AR Adverse Reaction  
BCVA  Best Corrected Visual Acuity  
CRF Case Report Form  
DED  Dry Eye Disease  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
IPL Intense Pulsed Light  
HIPAA  Health Insurance Portability and Accountability Act  
ICH International Conference on Harmonisation  
IND Investigational New Drug Application  
IPL Intense pulse light  
IRB Institutional  Review Board  
IUD Intrauterine Device  
KCS Keratoconjunctivitis Sicca  
ITT Intention -To-Treat  
MG Meibomian Gland  
MGD  Meibomian  Gland Dysfunction  
MGX Meibomian Gland Expression  
mm Millimeter  
Mm Hg  Millimeter of mercury  
MSDS  Material Safety Data Sheet  
NCT National Clinical Trial  
NIH  National Institutes of Health  
OPT Optimal pulse technology  
OSDI  Ocular surface disease index  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SLT Selective laser trabeculoplasty  
SOA  Schedule of Activities  
SOP Standard Operating Procedure  
UPT Urine pregnancy test 
US United States  
VAS Visual Analog Scale  
 
  
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  29 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version  Date  Description of Change  Brief Rationale  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  30   
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Intense Pulse Light Treatment with Meibomian Gland Expression o f 
the Upper Eyeids in Dry Eye Disease > Version 1 
Protocol TCLUM -001 27 Aug 2018  
NIH-FDA Clinical Trial Protoco l Template – v1.027 Aug 2017 8  31 11 REFERENCES  
 
  
J. Nelson, J. SHimazaki, J. Benitez -del-Castillo, J. Craig, J.McCulley, S. Den and G. Foulks, “The 
international workshop on Meibomian gland dysfunction: report of the definition and 
classification  subcommittee,” Invest Ophthalm. Vis. Sci. vol. 52, no. 4, pp. 1930 -7, 2011.  
 Cornea/External Disease Preferred Practice Pattern Panel, “Belpharitis Preferred Practice 
Pattern,” American Academy of Ophthalmology, 2013.  
 C. Raulin, B. Greve an dH. Grema, “IPL Technology: a review,” Lasers Su rg Med, vol. 32, no. 2, pp. 
78-87, 2003.  
 C. Kent, “Intense pulsed light: for treating dry eye (White Paper) 
*www.reviewofophthalmology.com/content/d/technology_update+”RevOphthalmol, 2010.  
 H. Larkin, “intense Pulsed Light: Skin treatment appears to clear M eibomian gland (White Paper) 
[http://issuu.com/eurotimes/docs/16 -4+”Eurotimes (ESCRS), vol. 16, no. 4, p 26, 2011.  
 R. Toyos, “Intense, pulsed light for dry eye syndrome (White Paper) 
*http://crstoday.com/2009/04/CRST0409_14.php},”Cat  Refract Surg  Today, no. April, pp 71 -3, 
2009.  
 R. Toyos, C. Buffa and S. Youngerman, “Case report: Dry -eye symptoms improve with intense 
pulsed light treatment ( www.eyeworld.org/article.php?sid=2698),”EyeWorld  (ASCRS), 
September 2005.  
 R. Toyos, W. McGill and D. Briscoe, “Intense pulsed light treatment for dry eye disease due to 
Meibomian gland dysfunction: a 3 -year retrospective study,”Photomed Laser Surg, vol. 33, no. 1, 
pp 41 -6, 2015.  
 S. Dell, “Intense pulsed  light for evaporative dry eye disease,”ClinOphthalmol., vol. 11 pp. 1167 -
73, 2017.  
 G. Vora and P. Gupta, “Intense pulsed light therapy for the treatment of evaporative dry eye 
disease,’ Curr OpinOphthalmol, vol. 26, pp. 314 -318, 2015.  
 S. Vegunta, D. Patel  and J. Shen, “Combination Therapy of Intense Pulsed Light Therapy and 
Meibomian Gland Expression (IPL/MGX) can improve dry eye symtoms and Meibomian gland 
function in patients with refractory dry eye: a retrospective analysis,” Cornea vol. 35, no. 3, pp 
318-322, 2016.  
 P. Gupta , G. Vora, C. Matossian, M. Kim and S. Stinnett, “Outcomes of intense pulsed light 
therapy for treatment of evaporative dry eye disease,” Can J Ophthalmol., vol. 51, no. 4, pp. 
249-53, 2016.  
 J. Albietz and K. Schmid, “Intense pulsed l ight treatment and meibomian gland expression for 
moderate to advanced Meibomian gland dysfunction,” ClinExpOptom, voldoi: 
10.1111/cxo.12541., 2017.  
 R. Liu, B. Rong, P. Tu, Y.Tang, W. Song, R. Toyos, M. Toyos and X. Yan, “Analysis of Cytokine 
Levels in Tea rs and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland 
Dysfunction,”Am J Ophthalmol vol. 183, pp. 81 -90, 2017.  
 J. Craig, Y. Chen and P. Turnbull, “Prospective trial of intense pulsed light for the treatment of 
Meibomian gland dysf unction,” Invest Ophthalmol Vis Sci, vol. 56, no. 3, pp 1965 -70, 2015.  
 X. Jiang, H.Lv, H. Song, M. Zhang, Y. Liu, X. Hu, X. Li and W. Wang, “Evaluation of the Safety and 
Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland 
Dysfunction, ”J.Ophthalmol, 2016.  